Bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 22 patient starts across both programs to date –


- Ended quarter with $227M in cash, cash equivalents, marketable securities and...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Massachusetts ,University Of Pennsylvania ,Michigan ,American ,Andrew Obenshain ,Janetl Kwiatkowski ,Alexisa Thompson ,Julie Kanter ,Division Of Hematology ,Department Of Pediatrics ,Thalassemia Center ,Nasdaq ,Perelman School Of Medicine ,Exchange Commission ,Drug Administration ,San Diego Convention Center ,American Society Of Hematology ,University Of Alabama ,Sickle Cell Disease Center ,Biologics Licensing Application ,Priority Review ,Prescription Drug User Fee Act ,Rare Pediatric Disease Priority Review Voucher ,American Society ,Annual Meeting ,Health Related Quality ,Sickle Cell Disease ,Who Have Received ,Gene Therapy ,Sickle Cell ,Improved Quality ,Pediatric Patients ,Post Treatment ,Perelman School ,Iron Burden ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Priority Review Voucher ,Consolidated Statements ,Markets ,